892药液治疗支气管肺癌的临床和实验研究  

Clinical and Experimental Studies on Medicinal Liquid No.892 in Treating Lung Cancer

作　　者：杨勤建[1] 雷良蔚[1] 潘希雄 郑国华[1] 鲁松清 李波[1] 张六通[1] 

机构地区：[1]湖北中医学院

出　　处：《中国中西医结合外科杂志》1998年第2期68-70,共3页Chinese Journal of Surgery of Integrated Traditional and Western Medicine

基　　金：湖北省科委重点课题

摘　　要：研究８９２号药液对支气管肺癌的抑癌作用。用Ｔ７３９近交系小鼠肺腺癌细胞移植于小鼠右前肢，随机分为７组，分别给予中药、化疗、中药加化疗，观察各组癌重、病理改变及ＩＬ－２、ＮＫ细胞、ＴＮＦ的变化；将５６例中晚期肺癌病人随机分为２组，给予中药加化疗、单用化疗治疗，观察主症、近期疗效、生存质量等变化。本研究表明８９２药液可抑制移植性Ｔ７３９近交系小鼠肺腺癌癌细胞生长，使之离散、变性、坏死，癌组织周围大量淋巴细胞、单核细胞浸润，并可提高荷癌小鼠脾ＩＬ－２、ＮＫ细胞活性及血清ＴＮＦ水平；加化疗提高ＮＫ细胞活性效果更明显；中药加化疗组近期疗效ＣＲ１例、ＰＲ９例、Ｓ１７例，（对照组ＰＲ５例、Ｓ７例），总有效率（ＣＲ＋ＰＲ）为３３．３３％，高于化疗对照组的１９．２３；在改善临床主症，提高生存质量，延长生存期等方面亦明显高于化疗对照组。８９２号药液对支气管肺癌有一定治疗作用。The medical liquid No.892(ML892) mainly composed of herbs to reduce phlegm and to resolve masses and herbs to activate blood circulation and to disperse stasis was prepared.The experimental results showed that ML892 inhibited the growth of adenocarcinoma cells of the lung in mice T739,causing dispersion,degeneration and necrosis of the adenocarcinoma cells promoted infiltration of lymphocytes and monocytes around the carcinoma tissue,increaesd the amount of TNF and raised the activities of IL2 and NK in mice with lung cancer.If ML892 was given with cyclophosphomidum the effect was more significant.Simultaneously,30 cases of middle and latestaged lung cancer were treated with ML892 associated with chemotherapeutic agents (26 cases treated with chemotherapeutic agents alone in control group). Short term results showed that CR,PR and S was in 1 case,9 and 5 cases respectively,but in the control group PR and S was in 5 and 7 cases respectively. It was showed the effects of relieving symptoms,improving life quality and prolonging survival time in the therapeutic group were better than those in the control group.

关 键 词：892药液 肺癌 中医药疗法 

分 类 号：R273.42[医药卫生—中西医结合]